Risk factors for Clostridium difficile-associated diarrhea and the effectiveness of prophylactic probiotic therapy

被引:10
作者
Mizui, T. [1 ]
Teramachi, H. [2 ]
Tachi, T. [2 ]
Tamura, K. [2 ]
Shiga, H. [2 ]
Komada, N. [2 ]
Umeda, M. [1 ]
Koda, A. [1 ]
Aoyama, S. [1 ]
Goto, C. [1 ]
Tsuchiya, T. [2 ]
机构
[1] Gifu Municipal Hosp, Dept Pharm, Gifu, Japan
[2] Gifu Pharmaceut Univ, Lab Clin Pharm, Gifu 5011196, Japan
来源
PHARMAZIE | 2013年 / 68卷 / 08期
关键词
ANTIBIOTIC-ASSOCIATED DIARRHEA; PREVENTION; COLITIS; DISEASE;
D O I
10.1691/ph.2013.3552
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Measures for prevention of Clostridium difficile-associated diarrhea, a common nosocomial infection, in hospital settings are urgently needed. This study was conducted to identify the risk factors contributing to C. difficile-associated diarrhea and to evaluate the clinical benefit of probiotics in its prevention. The study included 2716 patients at least 20 years old who received an injected antibiotic at any time between February 2010 and February 2011; a total of 2687 patients (98.9%) were assigned to the non-C. difficile-associated diarrhea group, and 29 patients (1.1%) were assigned to the C. difficile-associated diarrhea group. Univariate analysis revealed a significant difference between the two groups for the following factors: antibiotic therapy for >= 8 days; enteral nutrition; intravenous hyperalimentation; fasting; proton pump inhibitor use; H-2 blocker use; and serum albumin <= 2.9 g/dL (p <0.05). Multivariate logistic regression analysis revealed a significant difference between the two groups for several factors. Antibiotic therapy for >= 8 days, intravenous hyperalimentation, proton pump inhibitor use, and H-2 blocker use were therefore shown to be risk factors for C. difficile-associated diarrhea. Prophylactic probiotic therapy was not shown to suppress the occurrence of C. difficile-associated diarrhea.
引用
收藏
页码:706 / 710
页数:5
相关论文
共 18 条
[1]   Probiotics for prevention of antibiotic-associated diarrhea and Clostridium difficile-associated disease in hospitalized adults-A meta-analysis [J].
Avadhani, Amita ;
Miley, Helen .
JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS, 2011, 23 (06) :269-274
[2]   CLINDAMYCIN-ASSOCIATED COLITIS DUE TO A TOXIN-PRODUCING SPECIES OF CLOSTRIDIUM IN HAMSTERS [J].
BARTLETT, JG ;
ONDERDONK, AB ;
CISNEROS, RL ;
KASPER, DL .
JOURNAL OF INFECTIOUS DISEASES, 1977, 136 (05) :701-705
[3]  
Chonan K, 2010, J JPN SOC HOSP PHARM, V46, P665
[4]   Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea:: a systematic review [J].
Dendukuri, N ;
Costa, V ;
McGregor, M ;
Brophy, JM .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 173 (02) :167-170
[5]  
DEULIBARRI JI, 2005, NUTR HOSP, V20, P38
[6]   Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease [J].
Dial, S ;
Delaney, JAC ;
Barkun, AN ;
Suissa, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (23) :2989-2995
[7]   Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital [J].
Geric, B ;
Rupnik, M ;
Gerding, DN ;
Grabnar, M ;
Johnson, S .
JOURNAL OF MEDICAL MICROBIOLOGY, 2004, 53 (09) :887-894
[8]   Economic healthcare costs of Clostridium difficile infection: a systematic review [J].
Ghantoji, S. S. ;
Sail, K. ;
Lairson, D. R. ;
DuPont, H. L. ;
Garey, K. W. .
JOURNAL OF HOSPITAL INFECTION, 2010, 74 (04) :309-318
[9]  
Halim H. A., 1997, Journal of Clinical Pharmacy and Therapeutics, V22, P391, DOI 10.1046/j.1365-2710.1997.00119.x
[10]  
Hickson Mary, 2011, Therap Adv Gastroenterol, V4, P185, DOI 10.1177/1756283X11399115